255 filings
ARS
2023 FY
XENE
Xenon Pharmaceuticals Inc
26 Apr 24
Annual report to shareholders
4:27pm
DEF 14A
XENE
Xenon Pharmaceuticals Inc
Definitive proxy
26 Apr 24
4:26pm
8-K
XENE
Xenon Pharmaceuticals Inc
19 Apr 24
Departure of Directors or Certain Officers
4:21pm
8-K
XENE
Xenon Pharmaceuticals Inc
8 Mar 24
Other Events
5:27pm
10-K
2023 FY
XENE
Xenon Pharmaceuticals Inc
Annual report
29 Feb 24
4:36pm
8-K
tje2vwxbyim8kx1kt
29 Feb 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm
424B5
l3k491t 1k1w85cwbl
30 Nov 23
Prospectus supplement for primary offering
4:18pm
8-K
zj3ioy
30 Nov 23
Entry into a Material Definitive Agreement
4:15pm
424B5
6hsmi17n 0b4p25x4
29 Nov 23
Prospectus supplement for primary offering
5:05pm
8-K
2hhhufz3
27 Nov 23
Other Events
7:03am
8-K
4e2tws
9 Nov 23
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
4:06pm
8-K
eqwul3r
8 Nov 23
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
0mxd4jn1he52uv9k
9 Aug 23
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
j3qt1 v4q
8 Aug 23
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
4:07pm
8-K
xokqt5yd3exh
2 Jun 23
Submission of Matters to a Vote of Security Holders
4:08pm
8-K
hfa749t4z1 qf2hf
9 May 23
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
ARS
le7 mbz1qtp0i6abr
27 Apr 23
Annual report to shareholders
4:20pm